Core Viewpoint - DJS Law Group is investigating claims against RxSight, Inc. for potential violations of securities laws related to misleading statements and undisclosed information impacting investors [1][2]. Investigation Details - The investigation centers on RxSight's financial performance, particularly the decline in sales of Light Delivery Devices (LDD) and total revenue [2]. - RxSight reported a significant drop in key metrics and lowered its full-year financial guidance, attributing the changes to "adoption challenges" leading to an "LDD stall" [2]. - Following the financial report, RxSight's shares plummeted by nearly 38% on the announcement day [2].

Core Viewpoint - The Schall Law Firm is investigating claims against RxSight, Inc. for potential violations of securities laws following a significant decline in the company's stock price after disappointing financial results [1][2]. Financial Performance - RxSight reported a decline in sales of Light Delivery Devices (LDD) and light adjustable intraocular lenses (LAL), contributing to an overall revenue decrease [2]. - The company lowered its full-year guidance for 2025, citing "Adoption challenges over the last few quarters" as a primary reason for the stall in LDD sales [2]. - Following the announcement of these results on July 9, 2025, RxSight's shares fell by 37.8% [2]. Legal Investigation - The investigation by the Schall Law Firm focuses on whether RxSight made false or misleading statements or failed to disclose important information to investors [2].